To study sensitivity of a blood test to detect cancer cells in human blood for early diagnosis of cancer.
Not Applicable
Completed
- Conditions
- Health Condition 1: null- Breast, Colorectal, Lung, Cervix Uteri, Prostate, Stomach and Head & Neck Cancer
- Registration Number
- CTRI/2016/06/006985
- Lead Sponsor
- Actorius Innovations and Research Pvt Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 100
Inclusion Criteria
1. Written informed consent.
2. Confirmed diagnosis of stage 2-4 breast, lung, colorectal cervix uteri, prostate, stomach and head & neck cancer, (OR) no prior history of cancer.
3. Stage 2-4 treatment naive, metastatic, secondary, and recurrent cancer patients.
4. Able to undergo blood collection prior to initiation of chemotherapy treatment, (OR) able to provide blood sample if subject is a non-cancer control subject.
Exclusion Criteria
1. Patients unable to understand the research protocol and/or provide informed consent.
2. Patients with known immunodeficiency, or pregnancy.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The number of circulating tumor cells (CTCs) per milliliter of whole blood. Reported unit of measure will be the number of CTCs/milliliter. <br/ ><br>Timepoint: Blood samples will be collected from study subjects at a single timepoint and analyzed for the number of circulating tumor cells (CTCs) within 7 days (168 Hrs) of blood collection.
- Secondary Outcome Measures
Name Time Method ot ApplicableTimepoint: Not Applicable